share_log

Novo Integrated Sciences | S-1: General form for registration of securities under the Securities Act of 1933

Novo Integrated Sciences | S-1: General form for registration of securities under the Securities Act of 1933

Novo Integrated Sciences | S-1：證券上市註冊聲明
美股SEC公告 ·  07/08 17:18
Moomoo AI 已提取核心訊息
Novo Integrated Sciences, Inc. (Novo Integrated), a Nevada corporation, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 8, 2024, for the resale of up to 3,500,000 shares of common stock by Streeterville Capital, LLC. The shares are issuable upon conversion of a secured convertible promissory note with a maturity date of April 8, 2025, and a principal sum of $6,210,000. The note was sold in a private placement transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Novo Integrated will not receive any proceeds from the sale of the common stock by Streeterville Capital, LLC. The shares may be sold at fixed prices, prevailing market prices, or negotiated transactions, and the registration allows for the shares to be freely tradable upon sale. Novo Integrated is a healthcare company that integrates medical technology and interconnectivity to provide primary care and related wellness products.
Novo Integrated Sciences, Inc. (Novo Integrated), a Nevada corporation, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 8, 2024, for the resale of up to 3,500,000 shares of common stock by Streeterville Capital, LLC. The shares are issuable upon conversion of a secured convertible promissory note with a maturity date of April 8, 2025, and a principal sum of $6,210,000. The note was sold in a private placement transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Novo Integrated will not receive any proceeds from the sale of the common stock by Streeterville Capital, LLC. The shares may be sold at fixed prices, prevailing market prices, or negotiated transactions, and the registration allows for the shares to be freely tradable upon sale. Novo Integrated is a healthcare company that integrates medical technology and interconnectivity to provide primary care and related wellness products.
2024年7月8日，內華達州公司Novo Integrated Sciences, Inc.（以下簡稱Novo Integrated）向美國證券交易所（SEC）提交了一份登記聲明，以重新銷售Streeterville Capital，LLC最多350萬股普通股。這些股票可在2025年4月8日到期、本金爲6,210,000美元的擔保可轉換可兌付票據換股時發行。該票據於豁免1933年證券法第4條（a）（2）條規定的登記要求的私募交易中出售。Novo Integrated將不會從Streeterville Capital，LLC出售的普通股中獲得任何收益。這些股票可以以固定價格、盤中價格或協商交易方式出售，而登記信息允許這些股票在銷售後自由交易。Novo Integrated是一家醫療保健公司，將醫療技術和互聯互通融爲一體，提供初級醫療保健和相關健康產品。
2024年7月8日，內華達州公司Novo Integrated Sciences, Inc.（以下簡稱Novo Integrated）向美國證券交易所（SEC）提交了一份登記聲明，以重新銷售Streeterville Capital，LLC最多350萬股普通股。這些股票可在2025年4月8日到期、本金爲6,210,000美元的擔保可轉換可兌付票據換股時發行。該票據於豁免1933年證券法第4條（a）（2）條規定的登記要求的私募交易中出售。Novo Integrated將不會從Streeterville Capital，LLC出售的普通股中獲得任何收益。這些股票可以以固定價格、盤中價格或協商交易方式出售，而登記信息允許這些股票在銷售後自由交易。Novo Integrated是一家醫療保健公司，將醫療技術和互聯互通融爲一體，提供初級醫療保健和相關健康產品。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息